Zealand Pharma A/S (ZLDPF) Expected to Announce Earnings on Tuesday

Zealand Pharma A/S (OTCMKTS:ZLDPF) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Zealand Pharma A/S to post earnings of ($0.78) per share and revenue of $28.11 million for the quarter.

Zealand Pharma A/S Stock Up 0.1 %

Shares of Zealand Pharma A/S stock opened at $104.01 on Tuesday. The business has a 50-day simple moving average of $102.14 and a 200-day simple moving average of $114.10. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. Zealand Pharma A/S has a one year low of $67.58 and a one year high of $141.74.

Wall Street Analyst Weigh In

ZLDPF has been the subject of several analyst reports. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, January 21st. JPMorgan Chase & Co. assumed coverage on Zealand Pharma A/S in a report on Friday, November 8th. They issued an “overweight” rating on the stock.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.